CRIS Current Research Information System

MARTINELLI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.916
AS - Asia 29.604
EU - Europa 28.269
AF - Africa 2.201
SA - Sud America 1.946
Continente sconosciuto - Info sul continente non disponibili 71
OC - Oceania 44
Totale 99.051
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.548
CN - Cina 8.535
SG - Singapore 8.373
GB - Regno Unito 8.007
VN - Vietnam 6.675
IT - Italia 4.375
SE - Svezia 4.013
DE - Germania 3.530
HK - Hong Kong 2.180
IN - India 1.681
RU - Federazione Russa 1.534
BR - Brasile 1.434
FR - Francia 1.184
UA - Ucraina 1.026
IE - Irlanda 1.012
NL - Olanda 976
ZA - Sudafrica 641
KR - Corea 632
EE - Estonia 548
TG - Togo 545
JP - Giappone 452
CI - Costa d'Avorio 408
CH - Svizzera 406
FI - Finlandia 406
BG - Bulgaria 296
JO - Giordania 257
SC - Seychelles 251
CA - Canada 248
NG - Nigeria 245
AR - Argentina 238
GR - Grecia 190
BE - Belgio 184
IR - Iran 155
ID - Indonesia 151
AT - Austria 137
PL - Polonia 120
ES - Italia 90
TR - Turchia 89
EC - Ecuador 86
MX - Messico 84
BD - Bangladesh 73
EU - Europa 65
UZ - Uzbekistan 52
HR - Croazia 47
CL - Cile 46
LB - Libano 43
PY - Paraguay 40
IQ - Iraq 36
CO - Colombia 35
AU - Australia 33
MY - Malesia 32
RO - Romania 29
LT - Lituania 28
PH - Filippine 28
CZ - Repubblica Ceca 26
MA - Marocco 25
PE - Perù 22
VE - Venezuela 19
AE - Emirati Arabi Uniti 18
IL - Israele 17
EG - Egitto 16
PT - Portogallo 16
SA - Arabia Saudita 16
TW - Taiwan 16
DZ - Algeria 15
KE - Kenya 15
PK - Pakistan 15
TN - Tunisia 15
UY - Uruguay 13
RS - Serbia 12
KG - Kirghizistan 11
KZ - Kazakistan 10
NO - Norvegia 10
NZ - Nuova Zelanda 9
SK - Slovacchia (Repubblica Slovacca) 9
AL - Albania 8
DK - Danimarca 8
MK - Macedonia 8
HN - Honduras 7
HU - Ungheria 7
NP - Nepal 7
AZ - Azerbaigian 6
BA - Bosnia-Erzegovina 6
BO - Bolivia 6
CR - Costa Rica 6
A2 - ???statistics.table.value.countryCode.A2??? 5
GY - Guiana 5
KW - Kuwait 5
LU - Lussemburgo 5
QA - Qatar 5
BH - Bahrain 4
DO - Repubblica Dominicana 4
LA - Repubblica Popolare Democratica del Laos 4
PA - Panama 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
ET - Etiopia 3
GE - Georgia 3
KH - Cambogia 3
Totale 98.984
Salva come PNG Salva come JPEG
Città #
Southend 7.305
Singapore 5.416
Fairfield 4.103
Ashburn 3.807
Chandler 3.254
Dong Ket 2.581
Hong Kong 2.156
Houston 2.049
Woodbridge 2.048
Wilmington 1.894
Seattle 1.821
Ann Arbor 1.622
Hefei 1.439
Princeton 1.423
Cambridge 1.414
Beijing 1.331
Santa Clara 1.210
Dublin 1.005
Boardman 955
Ho Chi Minh City 844
Bologna 734
Nanjing 667
Hanoi 664
Westminster 651
Padova 623
Seoul 586
Lomé 545
Jacksonville 499
Los Angeles 458
Abidjan 407
New York 406
Tokyo 375
Berlin 347
Jinan 339
Bern 332
Helsinki 323
Shenyang 322
Saint Petersburg 321
Dallas 317
Milan 312
Medford 289
Sofia 285
Buffalo 277
Amman 256
Redondo Beach 250
Hebei 246
San Diego 236
Turin 236
Changsha 230
Nanchang 218
Munich 212
Bremen 197
Abeokuta 184
Frankfurt am Main 184
Redmond 178
Brussels 176
São Paulo 170
Tianjin 165
Florence 154
Jiaxing 148
Guangzhou 144
Bengaluru 142
Shanghai 140
Falls Church 138
Redwood City 138
Zhengzhou 131
Mülheim 125
Rome 125
Norwalk 110
Toronto 106
Hangzhou 103
Haiphong 99
Haikou 95
Chicago 94
Falkenstein 94
Phoenix 93
Jakarta 90
Taizhou 90
Ningbo 89
Nuremberg 83
London 81
Warsaw 79
Dearborn 78
Da Nang 77
Vienna 74
Biên Hòa 73
Mahé 71
Mountain View 71
Yubileyny 67
Des Moines 66
Hyderabad 60
Olalla 60
Amsterdam 59
Taiyuan 59
Bühl 57
Düsseldorf 54
Orem 54
Paris 54
Tongling 52
Turku 52
Totale 64.723
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 731
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 664
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 362
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 336
5′UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia 326
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 321
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 317
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 314
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 306
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 297
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 288
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 286
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 278
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 271
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 269
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 269
Network integration of multi-tumour omics data suggests novel targeting strategies 267
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 266
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 260
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 258
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 255
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 254
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 254
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 242
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 242
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 242
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 240
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 238
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 237
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 235
Cauliflower Mosaic Virus TAV, a Plant Virus Protein That Functions like Ribonuclease H1 and is Cytotoxic to Glioma Cells 234
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 232
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 231
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 231
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 229
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 227
Data Science for Health Image Alignment: A User-Friendly Open-Source ImageJ/Fiji Plugin for Aligning Multimodality/Immunohistochemistry/Immunofluorescence 2D Microscopy Images 226
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 224
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 222
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 219
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 215
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 213
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 212
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 211
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 211
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 210
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 209
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 208
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia 207
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma 206
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Advances in the treatment for haematological malignancies. 204
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 204
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 204
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 203
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 201
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 200
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 200
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 200
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 199
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 198
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 198
A case report of acute myeloid leukemia and neurofibromatosis 1 198
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 198
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 198
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 197
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 197
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 196
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 196
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 196
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 196
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 196
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 195
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 194
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 194
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 193
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 193
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 192
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 192
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 191
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 191
P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy 190
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 190
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 189
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 189
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 189
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 188
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 188
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 188
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 186
14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia 185
Totale 23.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 272.032
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 272.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.565 0 0 0 0 0 451 243 604 999 489 521 4.258
2021/202213.288 1.535 364 875 1.149 1.272 869 288 883 603 982 2.280 2.188
2022/202314.196 1.671 2.230 753 1.860 935 1.077 497 768 2.240 318 1.159 688
2023/20243.987 219 603 225 374 282 879 268 300 172 243 209 213
2024/202514.908 529 2.276 1.236 1.001 2.090 746 1.280 500 212 1.292 645 3.101
2025/202618.504 3.305 3.752 3.294 2.489 3.829 1.835 0 0 0 0 0 0
Totale 100.965